Heike Keilhack

Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology, and translational medicine with over 14 years of experience in oncology drug discovery in both small biotechnology companies and large pharmaceutical companies. She is currently the Chief Scientific Officer at Ribon Therapeutics where she is helping advance a novel set of therapeutics focused on targeting stress support pathways. Prior to joining Ribon, Dr. Keilhack was Senior Director of Biology at Epizyme where, among other responsibilities, she was the project leader for the company’s EZH2 inhibitor program, currently in late-stage clinical testing. Before that, she was a research fellow at Merck and the biology project lead for the company’s clinical-stage AKT inhibitor, MK-2206. Dr. Keilhack received her Ph.D. in Biochemistry at Friedrich Schiller University of Jena (Germany) and completed postdoctoral training at the Harvard Medical School. She earned a B.S. in Biochemistry at Martin Luther University of Halle-Wittenberg (Germany).